Bridge Biotherapeutics (KOSDAQ:A288330) - Share price, News & Analysis

A288330 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

A288330 Stock Overview

Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide.

Risk Analysis

Revenue has declined by 69.7% over the past year

Does not have meaningful revenue (₩2B)

Bridge Biotherapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bridge Biotherapeutics
Historical stock prices
Current Share Price	₩10,700.00
52 Week High	₩16,250.00
52 Week Low	₩10,300.00
Beta	0.66
1 Month Change	-21.90%
3 Month Change	-7.36%
1 Year Change	-18.94%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-40.88%

Shareholder Returns

	A288330	KR Biotechs	KR Market
7D	-2.7%	-2.8%	0.006%
1Y	-18.9%	-39.8%	-15.8%

Return vs Industry: A288330 exceeded the KR Biotechs industry which returned -39.8% over the past year.

Return vs Market: A288330 underperformed the KR Market which returned -15.8% over the past year.

Price Volatility

Is A288330's price volatile compared to industry and market?
A288330 volatility
A288330 Average Weekly Movement	6.2%
Biotechs Industry Average Movement	6.4%
Market Average Movement	5.5%
10% most volatile stocks in KR Market	10.3%
10% least volatile stocks in KR Market	3.2%

Stable Share Price: A288330 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: A288330's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2015	30	James Jungkue Lee	https://bridgebiorx.com

Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for the treatment of various fibrotic diseases, such as idiopathic pulmonary fibrosis. Bridge Biotherapeutics, Inc. has a research collaboration with Atomwise to launch small molecule programs across various therapeutic areas using structure-based AI technology for drug discovery.

Bridge Biotherapeutics Fundamentals Summary

How do Bridge Biotherapeutics's earnings and revenue compare to its market cap?
A288330 fundamental statistics
Market Cap	₩211.93b
Earnings (TTM)	-₩26.28b
Revenue (TTM)	₩1.92b

110.1x

P/S Ratio

-8.1x

P/E Ratio

Is A288330 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
A288330 income statement (TTM)
Revenue	₩1.92b
Cost of Revenue	₩1.18b
Gross Profit	₩746.43m
Other Expenses	₩27.02b
Earnings	-₩26.28b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-1.33k
Gross Margin	38.79%
Net Profit Margin	-1,365.70%
Debt/Equity Ratio	0%

How did A288330 perform over the long term?

See historical performance and comparison

Valuation

Is Bridge Biotherapeutics undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

4.92x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate A288330's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A288330's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: A288330 is unprofitable, so we can't compare its PE Ratio to the KR Biotechs industry average.

PE vs Market: A288330 is unprofitable, so we can't compare its PE Ratio to the KR market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate A288330's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: A288330 is overvalued based on its PB Ratio (4.9x) compared to the KR Biotechs industry average (3.3x).

Future Growth

How is Bridge Biotherapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

13.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bridge Biotherapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Bridge Biotherapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-36.6%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: A288330 is currently unprofitable.

Growing Profit Margin: A288330 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if A288330's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare A288330's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A288330 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20.1%).

Return on Equity

High ROE: A288330 has a negative Return on Equity (-61.05%), as it is currently unprofitable.

Financial Health

How is Bridge Biotherapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: A288330's short term assets (₩44.4B) exceed its short term liabilities (₩3.6B).

Long Term Liabilities: A288330's short term assets (₩44.4B) exceed its long term liabilities (₩53.6M).

Debt to Equity History and Analysis

Debt Level: A288330 is debt free.

Reducing Debt: A288330 had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A288330 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: A288330 has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 39.7% each year.

Dividend

What is Bridge Biotherapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate A288330's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A288330's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A288330's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A288330's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A288330 has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

James Jungkue Lee

no data

Tenure

Mr. James Jungkue Lee serves as Chief Executive Officer and Director at Bridge Biotherapeutics Inc. Mr. Lee founded Bridge Biotherapeutics, Inc. in 2015. Mr. James Jungkue Lee served as the Vice President...

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/17 00:00
End of Day Share Price	2022/05/17 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31